Page 23 - TD-3-3

Tumor Discovery Immune and epigenetic therapies for TNBC

doi: 10.1186/s13045-022-01341-0 doi: 10.1038/s41598-020-63539-x
84. Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti- 95. Luo N, Nixon MJ, Gonzalez-Ericsson PI, et al. DNA
PD-L1 antibody, in patients with locally advanced or methyltransferase inhibition upregulates MHC-I to
metastatic breast cancer: A phase 1b JAVELIN solid tumor potentiate cytotoxic T lymphocyte responses in breast
study. Breast Cancer Res Treat. 2018;167(3):671-686. cancer. Nat Commun. 2018;9(1):248.
doi: 10.1007/s10549-017-4537-5 doi: 10.1038/s41467-017-02630-w
85. Xie Y, Hu Y, Zhou N, et al. CAR T-cell therapy for triple- 96. Kakimi K, Karasaki T, Matsushita H, Sugie T. Advances
negative breast cancer: Where we are. Cancer Lett. in personalized cancer immunotherapy. Breast Cancer.
2020;491:121-131. 2017;24(1):16-24.
doi: 10.1016/j.canlet.2020.07.044 doi: 10.1007/s12282-016-0688-1
86. Simó-Riudalbas L, Esteller M. Targeting the histone 97. Sasidharan Nair V, El Salhat H, Taha RZ, John A, Ali BR,
orthography of cancer: Drugs for writers, erasers and Elkord E. DNA methylation and repressive H3K9 and
readers. Br J Pharmacol. 2014;172(11):2716-2732. H3K27 trimethylation in the promoter regions of PD-1,
doi: 10.1111/bph.12844 CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human
primary breast cancer. Clin Epigenetics. 2018;10(1):78.
87. Skvortsova K, Stirzaker C, Taberlay P. The DNA methylation
landscape in cancer. Essays Biochem. 2019;63:797-811. doi: 10.1186/s13148-018-0512-1
doi: 10.1042/EBC20190037 98. Li YC, Zhou Q, Song QK, et al. Overexpression of an
immune checkpoint (CD155) in breast cancer associated
88. Shukla A, Cloutier M, Santharam MA, Ramanathan S, with prognostic significance and exhausted tumor-
Ilangumaran S. The MHC class-I transactivator NLRC5:
Implications to cancer immunology and potential infiltrating lymphocytes: A cohort study. J Immunol Res.
applications to cancer immunotherapy. Int J Mol Sci. 2020;2020:3948928.
2021;22:1964. doi: 10.1155/2020/3948928
doi: 10.3390/ijms22041964 99. Huang W, Zhu Q, Shi Z, et al. Dual inhibitors of DNMT and
HDAC induce viral mimicry to induce antitumor immunity
89. Zeiner PS, Zinke J, Kowalewski DJ, et al. CD74 regulates
complexity of tumor cell HLA class II peptidome in brain in breast cancer. Cell Death Discov. 2024;10(1):143.
metastasis and is a positive prognostic marker for patient doi: 10.1038/s41420-024-01895-7
survival. Acta Neuropathol Commun. 2018;6(1):18.
100. Sheikh TN, Chen X, Xu X, et al. Growth inhibition and
doi: 10.1186/s40478-018-0521-5 induction of innate immune signaling of chondrosarcomas
90. Park SY, Park JW, Chun YS. Jumonji histone demethylases as with epigenetic inhibitors. Mol Cancer Ther.
emerging therapeutic targets. Pharmacol Res. 2016;105:146-151. 2021;20(12):2362-2371.
doi: 10.1016/j.phrs.2016.01.026 doi: 10.1158/1535-7163.MCT-21-0066
91. Guo L, Sang M, Liu Q, Fan X, Zhang X, Shan B. The 101. Kiyozumi Y, Baba Y, Okadome K, et al. Indoleamine
expression and clinical significance of melanoma- 2,3-dioxygenase 1 promoter hypomethylation is associated
associated antigen-A1, -A3 and -A11 in glioma. Oncol Lett. with poor prognosis in patients with esophageal cancer.
2013;6(1):55-62. Cancer Sci. 2019;110(6):1863-1871.
doi: 10.3892/ol.2013.1304 doi: 10.1111/cas.14028
92. Won JK, Bakhoum SF. The cytosolic DNA-sensing cGAS- 102. Zhai L, Bell A, Ladomersky E, et al. Immunosuppressive
STING pathway in cancer. Cancer Discov. 2020;10:26-39. IDO in cancer: Mechanisms of action, animal models, and
targeting strategies. Front Immunol. 2020;11:1185.
doi: 10.1158/2159-8290.CD-19-0761
doi: 10.3389/fimmu.2020.01185
93. Andres F, Yufeng L, Dongquan C, et al. Expression of the
MHC class II pathway in triple-negative breast cancer tumor 103. Hosseini A, Gharibi T, Marofi F, Babaloo Z, Baradaran B.
cells is associated with a good prognosis and infiltrating CTLA-4: From mechanism to autoimmune therapy. Int
lymphocytes. Cancer Immunol Res. 2016;4(5):390-399. Immunopharmacol. 2020;80:106221.
doi: 10.1158/2326-6066.CIR-15-0243 doi: 10.1016/j.intimp.2020.106221
94. Stewart RL, Matynia AP, Factor RE, Varley KE. Spatially- 104. Colamatteo A, Carbone F, Bruzzaniti S, et al. Molecular
resolved quantification of proteins in triple-negative breast mechanisms controlling Foxp3 expression in health and
cancers reveals differences in the immune microenvironment autoimmunity: From epigenetic to post-translational
associated with prognosis. Sci Rep. 2020;10(1):6598. regulation. Front Immunol. 2020;10:3136.

Volume 3 Issue 3 (2024) 17 doi: 10.36922/td.3383